Teladoc Health (TDOC) Shares Drop for Seven Consecutive Sessions, Losing Nearly 16%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Source: seekingalpha
- Stock Decline: Teladoc Health shares fell 3.3% on Thursday to $6.08, marking seven consecutive sessions of losses and a total decline of nearly 16%, indicating market concerns about its future performance.
- Rating Analysis: According to Seeking Alpha's Quant Rating, TDOC holds a 'Hold' rating with a score of 2.7 out of 5, receiving a B+ for profitability prospects but a D- for growth factors, highlighting challenges in growth.
- Analyst Opinions: While five Wall Street analysts rated TDOC as 'Buy' or higher, 22 analysts recommended 'Hold', with none issuing 'Sell' ratings, reflecting a divergence in market sentiment regarding its future outlook.
- Limited Acquisition Impact: Analysts noted that Teladoc's recent acquisitions of UpLift and Catapult Health have not significantly offset declining user numbers or driven innovation, indicating substantial challenges in user growth and product development.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TDOC
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.91 USD with a low forecast of 7.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 5.740
Low
7.50
Averages
8.91
High
12.00
Current: 5.740
Low
7.50
Averages
8.91
High
12.00
About TDOC
Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Impact Analysis of Medicare Policy Change on Teladoc
- Medicare Coverage Change: Medicare will end broad coverage for telehealth services at the end of the month, except for rural patients visiting medical facilities, which may put pressure on Teladoc's business.
- Pandemic Performance: Teladoc surged during the early pandemic by offering remote consultations, leading to significant revenue and stock price increases; however, as medical offices reopened, increased competition hindered sustained growth.
- Acquisition Impact: The acquisition of Livongo enhanced Teladoc's chronic care capabilities but was made at high valuations, failing to deliver the expected growth and adding financial strain to the company.
- Customer Structure Analysis: Teladoc's core revenue primarily comes from large enterprise clients, suggesting that the Medicare change may not significantly impact its income, yet the company still faces risks from sluggish growth and profitability challenges.
Continue Reading
Telehealth Companies Face Significant Challenges Ahead
- Medicare Policy Tightening: With Medicare provisions expiring on January 31, only patients receiving telehealth services from healthcare facilities or in rural areas will be reimbursed, significantly reducing demand for telehealth services and impacting both Teladoc and Doximity's business performance.
- Teladoc's Weak Performance: Despite having a vast patient network, Teladoc's revenue growth has been slow and it remains unprofitable; with the impending Medicare changes, 2026 is expected to pose even greater challenges, suggesting investors should approach with caution.
- Doximity's Limited Profitability: While Doximity remains profitable, its revenue growth has slowed considerably and failed to meet market expectations, compounded by the fact that 80% of U.S. physicians are already on the platform, hindering its expansion and future sales growth prospects.
- Negative Market Reaction: Teladoc and Doximity's stock prices fell by 4.13% and 3.00% respectively, reflecting investor pessimism regarding both companies' future performance, which may lead to further market sell-offs.
Continue Reading